Shares of United Laboratories International Holdings (UNITED LAB) plunged 5.53% in early trading on Tuesday, despite the company's recent $2 billion deal with Danish pharmaceutical giant Novo Nordisk and positive financial announcements. The sharp decline comes as investors reassess the long-term implications of the company's strategic moves.

On Monday, Novo Nordisk announced that it had acquired the global rights to United Laboratories' "triple-G" weight-loss drug candidate in a deal worth up to $2 billion. While this transaction represents a significant financial windfall for United Laboratories, some investors may be concerned that the company is parting ways with a potentially lucrative product in the rapidly growing obesity treatment market.

Adding to the complex market reaction, United Laboratories released its financial results for the fiscal year, reporting revenue of RMB 13.76 billion and net income of RMB 2,659.7 million. The company also declared a final dividend of RMB 28 cents per share and a special dividend of RMB 12 cents per share. Despite these positive financial indicators, the stock's sharp decline suggests that investors are more focused on the potential long-term impact of the Novo Nordisk deal on United Laboratories' future growth prospects.